8:30 am Morning Refreshments & Networking

9:00 am Chair’s Opening Remarks

Harnessing Novel Pathways Approach to Drive Preclinical Insights

9:10 am Turning the Undruggable Druggable into the Next Blockbuster: β-Catenin

Synopsis

• Highlighting the importance of β-catenin as THE target in the Wnt pathway relevant to cancer
• Providing approaches toward drugging β-catenin and other intractable targets, especially transcription factors
• Sharing progress to date on drugging β-catenin

9:40 am Demonstrating Efficacy in Wnt Ligand Dependent GI Cancers through a Porcupine Inhibitor

Synopsis

• Presenting preclinical oncology data which supports the genetic selection strategy of RXC004 in the clinic
• Sharing the mechanism of action of RXC004 in genetically defined cell lines

10:10 am Not All Wnt Mutations Are Equal: Stratifying Wnt Pathway Activation in Colorectal Cancer

  • Simon Leedham Professor of Molecular & Population Genetics, University of Oxford

Synopsis

• Describing the subdivision of mutations in CRC into ligand dependent and independent and how this leads to differences in downstream pathway modulation
• Sharing methods of identifying ligand dependent patients in clinical cohorts
• Providing therapeutic options available for both patient groups and connecting with immune regulation

10:40 am Inhibiting β-Catenin to Target “Drug-Tolerant Persister Cells” in Metastatic EGFR-Mutant Non-Small Cell Lung Cancer

  • Regan Memmot Assistant Professor in Medical Oncology , The Ohio State University

Synopsis

• Detailing how stabilization of β-catenin by EGFR TKIs (tyrosine kinase inhibitors) enriches for cancer cells with stem-like properties
• Demonstrating that EGFR TKIs increase the stability of β-catenin through a novel mechanism that is dependent on Notch3
• Providing combinational work for a β-catenin inhibitor with an EGFR TKI causes a deeper level of response in EGFR-mutant NSCLC

11:10 am Morning Networking

Synopsis

Break Network with other attendees in our quick-fire networking session. Grab a hot drink and let the computer match you randomly with a range of attendees in 1-1 formats. Make sure to click “connect” to swap virtual business cards

11:40 am Broken Wings: Wnt Signalling in Chronic Lung Disease

Synopsis

• Describing the current knowledge of Wnt pathway impairment in chronic lung disease
• Highlighting considerations in activation of Wnt for lung regeneration
• Sharing clinically relevant models to study regeneration

12:10 pm Wnt/β-Catenin Signaling Promotes Drug Tolerance & Resistance to Targeted Cancer Therapy

  • Trever Bivona Professor - Hematology & Oncology, University of California San Francisco

Synopsis

• Discuss how targeted cancer therapy is associated with activation of Wnt/β-catenin signaling
• Find out how Wnt/β-catenin signaling supports lineage plasticity during treatment
• Analyze how inhibiting Wnt/β-catenin signaling blocks this drug tolerance and resistance process and enhances response to targeted cancer therapy

12:40 pm Networking Lunch

1:40 pm A Novel Downstream Therapeutic Target in the Wnt/β-Catenin Pathway

  • Rahul Aras President & CEO, Iterion Therapeutics

Synopsis

• Discussing Tegavivint’s unique TBL-1 affinity and resulting oncogenic Wnt gene silencing without the toxicity of wider pathway disruption
• Sharing the safety and clinical activity in Phase 1/2a clinical studies for Desmoid tumor patients
• Guiding you through Iterion’s vision for wider clinical pursuits in other cancers involving nuclear β-catenin signaling, such as AML, NSCLC, and pediatric cancers

2:10 pm Targeting DKK1 in Cancer

  • Mike Kagey Senior Director of Translational Medicine , Leap Therapeutics

Synopsis

• Justifying the mechanistic rationale for neutralizing DKK1 in oncology
• Delving into the development of a DKK1 RNAscope biomarker assay
• Sharing results from their DisTinGuish clinical trial

2:40 pm Afternoon Refreshments & Networking

3:10 pm Wnt Modulating Antibodies for Tissue Regeneration

Synopsis

• Introducing Surrozen’s Wnt-modulating antibody platforms
• Sharing preclinical data from two of Surrozen’s most advanced Wnt-modulating bispecific antibodies
• Envisioning clinical directions for Surrozen’s therapeutic targeting and promising opportunities

3:40 pm ANTs: AntlerA Wnt-Mimetic Antibody Therapeutics for Regenerative Medicine

Synopsis

• Providing insight into ANT engineering practices
• Building an ANT library for understanding WNT biology and target validation
• Envisioning clinical applications for ANTs in a range of disease modalities

4:10 pm Chair’s Closing Remarks & End of Summit